La vendita allo scoperto per Chemomab Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Chemomab Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Chemomab Therapeutics (NASDAQ:CMMB) Azioni, Report sulle vendite allo scoperto

Chemomab Therapeutics

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics Ltd

Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) released its Q3 earnings on Thursday, October 24, 2024 at 04:05 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Boyd Gaming beat estimated earnings by 10.0%, reporting an EPS of $1.52 versus an estimate of $1.38.
Revenue was up $58.08 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.09 in the last quarter, resulting in a 4.0% increase share price change the following day.
Here's a look at Boyd Gaming's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.38</td>
<td>1.49</td>
<td>1.57</td>
<td>1.47</td>
<td>1.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.52</td>
<td>1.58</td>
<td>1.51</td>
<td>1.66</td>
<td>1.36</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>912.95M</td>
<td>909.06M</td>
<td>958.74M</td>
<td>930.47M</td>
<td>879.82M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>961.25M</td>
<td>967.51M</td>
<td>960.52M</td>
<td>954.41M</td>
<td>903.16M</td>
</tr>
</tbody>
</table>

<h3>Competitors' Recent Earnings Updates</h3>
It's important to consider Boyd Gaming's numbers in relation to how its competitors, like PENN Entertainment, Golden Entertainment, and Inspired Entertainment, have been performing.
<ul>
<li>PENN Entertainment announced strong earnings on August 08, 2024, surpassing market expectations. Despite an estimated EPS of $-0.26, PENN Entertainment's actual EPS was $-0.18, reflecting a 30.77% increase.</li>
<li>Despite market projections of an EPS of $0.21, Golden Entertainment's earnings on August 08, 2024 fell short with an actual EPS of $0.02, representing a -90.48% decrease from expectations.</li>
<li>The latest earnings announcement from Inspired Entertainment on August 08, 2024 exceeded expectations, with an actual EPS of $0.2 compared to the market's estimate of $0.1, resulting in a 100.0% increase.</li>
</ul>
<h3>Insights into Competitors' Quarterly Earnings and Stock Performance</h3>
The analysis presented here offers insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Date</th>
<th style="text-align: right;">EPS Expected</th>
<th style="text-align: right;">EPS Announced</th>
<th>EPS Change Percent</th>
<th>Stock Price At Close</th>
<th>Stock Price at Next Day Open</th>
<th>Price Change Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd Gaming</td>
<td>October 24, 2024</td>
<td style="text-align: right;">1.38</td>
<td style="text-align: right;">1.52</td>
<td>10.14%</td>
<td>$64.31</td>
<td>$69.96</td>
<td>8.79%</td>
</tr>
<tr>
<td>PENN Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.26</td>
<td style="text-align: right;">-0.18</td>
<td>30.77%</td>
<td>$18.72</td>
<td>$18.83</td>
<td>0.59%</td>
</tr>
<tr>
<td>Golden Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.21</td>
<td style="text-align: right;">0.02</td>
<td>-90.48%</td>
<td>$28.12</td>
<td>$27.42</td>
<td>-2.49%</td>
</tr>
<tr>
<td>Inspired Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.10</td>
<td style="text-align: right;">0.20</td>
<td>100.0%</td>
<td>$8.48</td>
<td>$8.39</td>
<td>-1.06%</td>
</tr>
</tbody>
</table>

<h3>Analyzing Peer Revenue Discrepancy: Estimated vs. Announced</h3>
Here's a comparison table presenting estimated and announced revenue figures for Boyd Gaming's peers. This comparison offers insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Estimated Revenue</th>
<th>Announced Revenue</th>
<th>Revenue Surprise Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd Gaming</td>
<td>912.95M</td>
<td>961.25M</td>
<td>5.29%</td>
</tr>
<tr>
<td>PENN Entertainment</td>
<td>1.66B</td>
<td>1.66B</td>
<td>0.18%</td>
</tr>
<tr>
<td>Golden Entertainment</td>
<td>174.60M</td>
<td>167.33M</td>
<td>-4.16%</td>
</tr>
<tr>
<td>Inspired Entertainment</td>
<td>74.41M</td>
<td>75.60M</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

To track all earnings releases for Boyd Gaming <a href="https://www.benzinga.com/quote/BYD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Boyd Gaming Earnings Review: Q3 Summary

AG Mortgage Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.16 by 6.25 percent.

Earnings Beats

News

MITT

AG Mortgage Investment Q3 2024 Adj EPS $0.17 Beats $0.16 Estimate

WIIM

NXPI

NXP Semiconductors shares are trading lower after the company issued soft guidance.

2024 Outlook
The company raised its 2024 outlook for organic revenue growth to reflect strong year-to-date performance. All other measures in the outlook were maintained.
The company's outlook for 2024 in the table below assumes constant currency rates and excludes the impact of any future acquisitions or dispositions that may occur during the remainder of the year. Thomson Reuters believes that this type of guidance provides useful insight into the anticipated performance of its businesses.
The company expects its fourth-quarter 2024 organic revenue growth to be approximately 5% and its adjusted EBITDA margin to be approximately 37%.
The company continues to operate in an uncertain macroeconomic environment, reflecting ongoing geopolitical risk, uneven economic growth and an evolving interest rate and inflationary backdrop. Any worsening of the global economic or business environment, among other factors, could impact the company's ability to achieve its outlook.
Reported Full-Year 2023 Results and Full-Year 2024 Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Total Thomson Reuters</td>
<td colspan="1" rowspan="1">
FY 2023
Reported
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
2/8/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
5/2/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
8/1/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
11/5/2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue Growth</td>
<td colspan="1" rowspan="1">3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">6.5% - 7.0%</td>
<td colspan="1" rowspan="1">~ 7.0%</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Organic Revenue Growth(1)</td>
<td colspan="1" rowspan="1">6&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6%</td>
<td colspan="1" rowspan="1">6.0% - 6.5%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">~7.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin(1)</td>
<td colspan="1" rowspan="1">39.3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 38%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Corporate Costs</td>
<td colspan="1" rowspan="1">$115 million</td>
<td colspan="1" rowspan="1">$120 - $130 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow(1)</td>
<td colspan="1" rowspan="1">$1.9 billion</td>
<td colspan="1" rowspan="1">~ $1.8 billion</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Accrued Capex as % of Revenues(1)</td>
<td colspan="1" rowspan="1">7.8&nbsp;%</td>
<td colspan="1" rowspan="1">~ 8.5%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Depreciation &amp; Amortization of Computer Software
&nbsp;&nbsp;&nbsp; Depreciation &amp; Amortization of Internally
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Developed Software
&nbsp;&nbsp;&nbsp; Amortization of Acquired Software
</td>
<td colspan="1" rowspan="1">
$628 million
 $556 million
$72 million
</td>
<td colspan="1" rowspan="1">
$730 - $750 million
 $595 - $615 million
~ $135 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
<td colspan="1" rowspan="1">
Unchanged
 $580 - $600 million
~ $150 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest Expense (P&amp;L)(2)</td>
<td colspan="1" rowspan="1">$164 million(2)</td>
<td colspan="1" rowspan="1">$150 - $170 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">$125 - $145&nbsp; million</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective Tax Rate on Adjusted Earnings(1)</td>
<td colspan="1" rowspan="1">16.5&nbsp;%</td>
<td colspan="1" rowspan="1">~ 18%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Thomson Reuters Affirms FY24 Sales Guidance Of $7.27B Vs. $7.28B Estimate

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) reported quarterly earnings of $1.74 per share which missed the analyst consensus estimate of $1.87 by 6.95 percent. The company reported quarterly sales of $260.900 million which missed the analyst consensus estimate of $264.467 million by 1.35 percent. This is a 4.07 percent increase over sales of $250.700 million the same period last year.

Earnings Misses

Enpro Q3 2024 Adj. EPS $1.74 Misses $1.87 Estimate, Sales $260.900M Miss $264.467M Estimate

PLTR

Palantir shares are trading higher after the company reported better-than-expected Q3 financial results and issued guidance above consensus estimates.

MNDO

MIND C.T.I. Q3 EPS $0.04 Down From $0.06 YoY, Sales $5.21M Down From $5.26M YoY

Truist Securities analyst Jamie Cook upgrades MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) from Hold to Buy and raises the price target from $133 to $173.

Upgrades

Price Target

Analyst Ratings

Truist Securities Upgrades MasTec to Buy, Raises Price Target to $173

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) lowers FY2024 Adj EPS guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 analyst estimate..

Enpro Lowers FY2024 Adj EPS Guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 Est

Westlake Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.36 by 41.67 percent. The company reported quarterly sales of $276.995 million which beat the analyst consensus estimate of $244.000 million by 13.52 percent. This is a 13.89 percent decrease over sales of $321.664 million the same period last year.

WLKP

Westlake Chemical Q3 2024 GAAP EPS $0.51 Beats $0.36 Estimate, Sales $276.995M Beat $244.000M Estimate

Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) affirms FY2024 sales outlook from $65.00 million-67.00 million to $65.00 million-67.00 million.

SOPH

Sophia Genetics Affirms FY2024 Sales Guidance to $65.00M-67.00M  VS Est. 65.66M

Biotech

Health Care

General

BEAM

Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027

Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.47 by 0.68 percent. This is a 14.73 percent increase over earnings of $1.29 per share from the same period last year. The company reported quarterly sales of $4.619 billion which beat the analyst consensus estimate of $4.566 billion by 1.16 percent. This is a 12.93 percent increase over sales of $4.090 billion the same period last year.

Emerson Electric Q4 2024 Adj. EPS $1.48 Beats $1.47 Estimate, Sales $4.619B Beat $4.566B Estimate

Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) reported quarterly earnings of $1.41 per share which missed the analyst consensus estimate of $2.21 by 36.2 percent. The company reported quarterly sales of $3.117 billion which missed the analyst consensus estimate of $3.305 billion by 5.69 percent. This is a 0.06 percent increase over sales of $3.115 billion the same period last year.

Westlake Q3 2024 Adj. EPS $1.41 Misses $2.21 Estimate, Sales $3.117B Miss $3.305B Estimate

Hyster Yale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) reported quarterly earnings of $0.97 per share which missed the analyst consensus estimate of $1.97 by 50.76 percent. This is a 52.91 percent decrease over earnings of $2.06 per share from the same period last year. The company reported quarterly sales of $1.02 billion which missed the analyst consensus estimate of $1.06 billion by 3.82 percent. This is a 1.50 percent increase over sales of $1.00 billion the same period last year.

Hyster Yale Q3 2024 GAAP EPS $0.97 Misses $1.97 Estimate, Sales $1.02B Miss $1.06B Estimate

Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.19) by 48.74 percent. This is a 45.08 percent decrease over losses of $(1.22) per share from the same period last year. The company reported quarterly sales of $14.27 million which missed the analyst consensus estimate of $14.50 million by 1.58 percent. This is a 17.01 percent decrease over sales of $17.19 million the same period last year.

Beam Therapeutics Q3 2024 GAAP EPS $(1.77) Misses $(1.19) Estimate, Sales $14.27M Miss $14.50M Estimate

Thomson Reuters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRI#NYSE">TRI</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.77 by 3.9 percent. This is a 2.44 percent decrease over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $1.720 billion which beat the analyst consensus estimate of $1.713 billion by 0.39 percent. This is a 7.90 percent increase over sales of $1.594 billion the same period last year.

Thomson Reuters Q3 2024 Adj. EPS $0.80 Beats $0.77 Estimate, Sales $1.720B Beat $1.713B Estimate

Restaurant Brands International shares are trading lower following worse-than-expected Q3 financial results.

PINC

Premier Q1 2025 Adj. EPS $0.34 Beats $0.25 Estimate, Sales $248.142M Beat $232.843M Estimate

Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) reported quarterly earnings of $0.93 per share which missed the analyst consensus estimate of $0.95 by 2.11 percent. The company reported quarterly sales of $2.291 billion which missed the analyst consensus estimate of $2.307 billion by 0.69 percent. This is a 24.71 percent increase over sales of $1.837 billion the same period last year.

Restaurant Brands Intl Q3 2024 Adj. EPS $0.93 Misses $0.95 Estimate, Sales $2.291B Miss $2.307B Estimate

Oppenheimer analyst Jeff Jones maintained a Buy rating on Chemomab Therapeutics (CMMB – Research Report) today and set a price target of $13.00. Th...

Chemomab Therapeutics (CMMB) Gets a Buy from Oppenheimer

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on CMMB stock, giving a Buy rating today. Michael Okunewitch has given h...

Chemomab Therapeutics: Strong Buy Rating on Robust Financials and Positive Clinical Trial Outcomes

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) just reported results for the second quarter of 2024.<ul><li>Chemomab Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/cmmb-stock-earnings-chemomab-therapeutics-for-q2-of-2024/">CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024

Chemomab Therapeutics (CMMB) has released an update. Chemomab Therapeutics Ltd. invites shareholders to a Special General Meeting on November 18, 2...

Chemomab Therapeutics Announces Shareholder Meeting

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Argenx Se (ARGX – Research Report), Chemomab Therape...

Wall Street Analysts Are Bullish on Top Healthcare Picks

ARGX

CMMB

Press Releases

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Financing

Chemomab Therapeutics Announces $10 Million Private Placement

Markets

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Present at September 2024 Investor Conferences

Chemomab Therapeutics to Present at October 2024 Investor Conferences

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

Comments

Chemomab Therapeutics

Vendite allo scoperto

Chemomab Therapeutics (NASDAQ:CMMB) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO